JP2018525401A - 5−アミノレブリン酸がコンジュゲートされた量子ドットナノ粒子 - Google Patents
5−アミノレブリン酸がコンジュゲートされた量子ドットナノ粒子 Download PDFInfo
- Publication number
- JP2018525401A JP2018525401A JP2018508735A JP2018508735A JP2018525401A JP 2018525401 A JP2018525401 A JP 2018525401A JP 2018508735 A JP2018508735 A JP 2018508735A JP 2018508735 A JP2018508735 A JP 2018508735A JP 2018525401 A JP2018525401 A JP 2018525401A
- Authority
- JP
- Japan
- Prior art keywords
- ala
- nanoparticles
- quantum dot
- nanoparticle
- nanoparticle conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 130
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 229960002749 aminolevulinic acid Drugs 0.000 title claims abstract description 55
- 239000002096 quantum dot Substances 0.000 title claims abstract description 25
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 28
- 201000011510 cancer Diseases 0.000 claims abstract description 23
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 18
- 238000002428 photodynamic therapy Methods 0.000 claims abstract description 12
- 239000002243 precursor Substances 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 31
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical group CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 claims description 24
- 229950003776 protoporphyrin Drugs 0.000 claims description 24
- 239000003446 ligand Substances 0.000 claims description 14
- 230000001678 irradiating effect Effects 0.000 claims description 10
- 239000007822 coupling agent Substances 0.000 claims description 8
- 239000002207 metabolite Substances 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 239000004065 semiconductor Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000011258 core-shell material Substances 0.000 claims description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 239000007850 fluorescent dye Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229910052793 cadmium Inorganic materials 0.000 claims description 3
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 claims description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical group Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 2
- 230000001268 conjugating effect Effects 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 description 21
- 230000000737 periodic effect Effects 0.000 description 16
- -1 ester derivative of 5-ALA Chemical class 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 8
- 230000005284 excitation Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000011162 core material Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- BXGTVNLGPMZLAZ-UHFFFAOYSA-N n'-ethylmethanediimine;hydrochloride Chemical compound Cl.CCN=C=N BXGTVNLGPMZLAZ-UHFFFAOYSA-N 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000007970 thio esters Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052984 zinc sulfide Inorganic materials 0.000 description 3
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000011234 nano-particulate material Substances 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 238000001126 phototherapy Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910052761 rare earth metal Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- YBNMDCCMCLUHBL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-pyren-1-ylbutanoate Chemical compound C=1C=C(C2=C34)C=CC3=CC=CC4=CC=C2C=1CCCC(=O)ON1C(=O)CCC1=O YBNMDCCMCLUHBL-UHFFFAOYSA-N 0.000 description 1
- PVFFUHAAOKXVTK-UHFFFAOYSA-N 2-(methylamino)-4-oxopentanoic acid Chemical compound CNC(C(O)=O)CC(C)=O PVFFUHAAOKXVTK-UHFFFAOYSA-N 0.000 description 1
- OLFPHTDTKOOORK-UHFFFAOYSA-N 2-amino-2-(2-oxopropyl)octanoic acid Chemical compound CCCCCCC(N)(C(O)=O)CC(C)=O OLFPHTDTKOOORK-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229910017115 AlSb Inorganic materials 0.000 description 1
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 description 1
- 229910015808 BaTe Inorganic materials 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229910004813 CaTe Inorganic materials 0.000 description 1
- 229910004613 CdTe Inorganic materials 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229910002601 GaN Inorganic materials 0.000 description 1
- 229910005540 GaP Inorganic materials 0.000 description 1
- 229910005542 GaSb Inorganic materials 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- 229910005900 GeTe Inorganic materials 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229910004262 HgTe Inorganic materials 0.000 description 1
- 229910000673 Indium arsenide Inorganic materials 0.000 description 1
- GPXJNWSHGFTCBW-UHFFFAOYSA-N Indium phosphide Chemical compound [In]#P GPXJNWSHGFTCBW-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910017680 MgTe Inorganic materials 0.000 description 1
- 229910002665 PbTe Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229910005642 SnTe Inorganic materials 0.000 description 1
- 229910004411 SrTe Inorganic materials 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 239000005083 Zinc sulfide Substances 0.000 description 1
- 229910007709 ZnTe Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- LZYXPFZBAZTOCH-UHFFFAOYSA-N hexyl 5-amino-4-oxopentanoate;hydron;chloride Chemical compound Cl.CCCCCCOC(=O)CCC(=O)CN LZYXPFZBAZTOCH-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- WPYVAWXEWQSOGY-UHFFFAOYSA-N indium antimonide Chemical compound [Sb]#[In] WPYVAWXEWQSOGY-UHFFFAOYSA-N 0.000 description 1
- RPQDHPTXJYYUPQ-UHFFFAOYSA-N indium arsenide Chemical compound [In]#[As] RPQDHPTXJYYUPQ-UHFFFAOYSA-N 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 229940109328 photofrin Drugs 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920006380 polyphenylene oxide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- SBIBMFFZSBJNJF-UHFFFAOYSA-N selenium;zinc Chemical compound [Se]=[Zn] SBIBMFFZSBJNJF-UHFFFAOYSA-N 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- OCGWQDWYSQAFTO-UHFFFAOYSA-N tellanylidenelead Chemical compound [Pb]=[Te] OCGWQDWYSQAFTO-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DRDVZXDWVBGGMH-UHFFFAOYSA-N zinc;sulfide Chemical compound [S-2].[Zn+2] DRDVZXDWVBGGMH-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
- A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/007—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests for contrast media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/927—Diagnostic contrast agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ceramic Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
Abstract
Description
一例は不動態化層である。QDを調製するプロセスでは、どんなナノ粒子でも最終無機表面原子の周りの配位が不完全であり、粒子の表面に、配位が不完全な高度に反応性の原子「ダングリングボンド」が生じ、これが粒子の凝集をもたらすことがある。この問題を解消するために、有機不動態化層を用いて、露出面の原子を保護有機基で覆うことができるが、不動態化層は有機官能基を具えるため、該官能基を通じて、他の材料への化学的結合が起こり得る。
<5−ALA n−アルキルエステル>
5−ALAメチルエステル(メチルアミノレブリン酸、商品名METVIV(登録商標))
5−ALAエチルエステル
5−ALAプロピルエステル
5−ALAブチルエステル
5−ALAペンチルエステル
5−ALAヘキシルエステル(ヘキシルアミノレブリン酸、商品名HEXVIX)
5−ALAオクチルエステル
同様に、
5−ALA(ヒドロキシメチル)テトラヒドロフラニルエステル;及び
5−ALAポリエチレングリコール誘導体
さらに、5−ALA・HClなどの塩類
Claims (20)
- 5−アミノレブリン酸にコンジュゲートされた官能化量子ドットナノ粒子。
- ナノ粒子が、アミド又はエステル結合により、5−ALAに共有結合されている、請求項1の5−ALA−ナノ粒子コンジュゲート。
- 量子ドットナノ粒子は、コア−シェルナノ粒子である、請求項1の官能化量子ドットナノ粒子。
- 癌細胞を標的にすることができるリガンドをさらに含む、請求項1の官能化量子ドットナノ粒子。
- リガンドは、PLZ4である、請求項1の官能化量子ドットナノ粒子。
- 量子ドットナノ粒子は、カドミウムを実質的に含まない、請求項の官能化量子ドットナノ粒子。
- 5−ALA−ナノ粒子コンジュゲートを調製する方法であって、
分子クラスター化合物、コア半導体材料、及び外層を含むナノ粒子を準備するステップと、
カップリング剤を準備するステップと、
5−ALA、5−ALA誘導体又は5−ALA類似体を準備するステップと、
前記準備したものが混合された混合物をインキュベートして粗製5−ALA−ナノ粒子コンジュゲートを生成するステップと、
粗製5−ALA−ナノ粒子コンジュゲートを精製するステップと、
5−ALA−ナノ粒子コンジュゲートを分離するステップと、を含む、方法。 - カップリング剤は、1−(3−ジメチルアミノプロピル)−3−エチルカルボジイミド塩酸塩である、請求項7の方法。
- 5−ALA−ナノ粒子コンジュゲートを、癌細胞を標的にすることができるリガンドにコンジュゲートするステップをさらに含む、請求項7の方法。
- 細胞のアポトーシスを誘導する方法であって、
複数の5−アミノレブリン酸にコンジュゲートされた官能化ナノ粒子を、それを必要とする哺乳動物に投与するステップと、
5−アミノレブリン酸に代謝産物を生成させるステップと、
生成された代謝産物を照射するステップと、を含む、方法。 - 代謝産物はプロトポルフィリンIXである、請求項10の方法。
- 照射するステップは、ナノ粒子によって行われる、請求項10の方法。
- ナノ粒子は、375〜475nmの範囲の光を発する、請求項12の方法。
- 照射するステップは、活性酸素種を生成するのに十分である、請求項10の方法。
- 官能化ナノ粒子は、癌細胞を標的にすることができるリガンドをさらに含む、請求項10の方法。
- リガンドを癌細胞に結合するステップをさらに含む、請求項15の方法。
- 癌細胞を検出する方法であって、
光線力学療法において5−ALA−ナノ粒子コンジュゲートを蛍光標識及び光増感剤の両方の前駆体として投与するステップと、
5−ALAをナノ粒子から分離するステップと、
5−ALAからPpIXを生成するステップと、
分離されたナノ粒子を励起して375〜475nmの青色光を発するステップと、
PpIXの蛍光特性を活性化するステップと、
蛍光を画像化するステップと、を含む、方法。 - 投与するステップは、注射によって行なわれる、請求項17の方法。
- 注射は、静脈内に行われる、請求項18の方法。
- ナノ粒子は、合金化された量子ドットである、請求項19の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562205998P | 2015-08-17 | 2015-08-17 | |
US62/205,998 | 2015-08-17 | ||
PCT/GB2016/052548 WO2017029501A1 (en) | 2015-08-17 | 2016-08-17 | 5-aminolevulinic acid conjugated quantum dot nanoparticle |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018525401A true JP2018525401A (ja) | 2018-09-06 |
JP6826105B2 JP6826105B2 (ja) | 2021-02-03 |
Family
ID=56842964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018508735A Active JP6826105B2 (ja) | 2015-08-17 | 2016-08-17 | 5−アミノレブリン酸がコンジュゲートされた量子ドットナノ粒子 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20170049891A1 (ja) |
EP (1) | EP3337510A1 (ja) |
JP (1) | JP6826105B2 (ja) |
KR (2) | KR102145331B1 (ja) |
CN (1) | CN108289956A (ja) |
TW (1) | TWI653050B (ja) |
WO (1) | WO2017029501A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021500329A (ja) * | 2017-10-18 | 2021-01-07 | ナノコ テクノロジーズ リミテッド | 5−アミノレブリン酸を用いて医用画像処理及び光線療法を向上させる方法 |
WO2020120970A1 (en) * | 2018-12-13 | 2020-06-18 | Nanoco Technologies Ltd | Methods for enhancing indocyanine green medical imaging and phototherapy |
KR102409219B1 (ko) * | 2020-11-17 | 2022-06-15 | 연세대학교 산학협력단 | 양자점을 포함하는 나노복합체의 안정성 평가방법 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020127224A1 (en) * | 2001-03-02 | 2002-09-12 | James Chen | Use of photoluminescent nanoparticles for photodynamic therapy |
US20100183504A1 (en) * | 2007-06-14 | 2010-07-22 | Fanqing Frank Chen | Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics |
US20110070443A1 (en) * | 2004-04-30 | 2011-03-24 | Nanoco Technologies Limited | Preparation of Nanoparticle Materials |
US20120230994A1 (en) * | 2009-09-24 | 2012-09-13 | The Regents Of The University of California, Office of Technology | Bladder cancer specific ligand peptides |
US20140044791A1 (en) * | 2011-02-04 | 2014-02-13 | Case Western Reserve University | Targeted nanoparticle conjugates |
US20140220143A1 (en) * | 2011-07-15 | 2014-08-07 | Shanta Dhar | Immune-stimulating photoactive hybrid nanoparticles |
WO2015101779A1 (en) * | 2014-01-06 | 2015-07-09 | Nanoco Technologies Ltd | Cadmium-free quantum dot nanoparticles |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0018527D0 (en) | 2000-07-27 | 2000-09-13 | Photocure Asa | Composition |
US7588828B2 (en) | 2004-04-30 | 2009-09-15 | Nanoco Technologies Limited | Preparation of nanoparticle materials |
GB0522027D0 (en) | 2005-10-28 | 2005-12-07 | Nanoco Technologies Ltd | Controlled preparation of nanoparticle materials |
KR101288460B1 (ko) * | 2009-06-26 | 2013-07-26 | 주식회사 진코스 | 양자점-클로린 유도체의 접합체를 함유하는 광감작제 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료 및 진단용 조성물 |
-
2016
- 2016-08-12 US US15/235,362 patent/US20170049891A1/en not_active Abandoned
- 2016-08-16 TW TW105126130A patent/TWI653050B/zh not_active IP Right Cessation
- 2016-08-17 KR KR1020187006882A patent/KR102145331B1/ko active IP Right Grant
- 2016-08-17 JP JP2018508735A patent/JP6826105B2/ja active Active
- 2016-08-17 KR KR1020207022466A patent/KR20200096329A/ko not_active Application Discontinuation
- 2016-08-17 WO PCT/GB2016/052548 patent/WO2017029501A1/en active Application Filing
- 2016-08-17 EP EP16757928.3A patent/EP3337510A1/en not_active Withdrawn
- 2016-08-17 CN CN201680054241.1A patent/CN108289956A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020127224A1 (en) * | 2001-03-02 | 2002-09-12 | James Chen | Use of photoluminescent nanoparticles for photodynamic therapy |
US20110070443A1 (en) * | 2004-04-30 | 2011-03-24 | Nanoco Technologies Limited | Preparation of Nanoparticle Materials |
US20100183504A1 (en) * | 2007-06-14 | 2010-07-22 | Fanqing Frank Chen | Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics |
US20120230994A1 (en) * | 2009-09-24 | 2012-09-13 | The Regents Of The University of California, Office of Technology | Bladder cancer specific ligand peptides |
US20140044791A1 (en) * | 2011-02-04 | 2014-02-13 | Case Western Reserve University | Targeted nanoparticle conjugates |
US20140220143A1 (en) * | 2011-07-15 | 2014-08-07 | Shanta Dhar | Immune-stimulating photoactive hybrid nanoparticles |
WO2015101779A1 (en) * | 2014-01-06 | 2015-07-09 | Nanoco Technologies Ltd | Cadmium-free quantum dot nanoparticles |
Non-Patent Citations (10)
Title |
---|
CHEM.COMMUN., vol. 49, JPN6019003705, 2013, pages 8934 - 8936, ISSN: 0004384696 * |
GASTROENTEROLOGY, vol. Vol.144, Issue5, Supplement 1, JPN6019003723, May 2013 (2013-05-01), pages 516, ISSN: 0004384693 * |
NANOMEDICINE, vol. 3, no. 6, JPN6019003711, 24 November 2008 (2008-11-24), ISSN: 0004384690 * |
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, vol. 10, JPN6019003708, 2013, pages 382 - 388, ISSN: 0004384698 * |
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, vol. 8, JPN6019003722, 2011, pages 14 - 29, ISSN: 0004384699 * |
PHYS.CHEM.CHEM.PHYS., vol. 17, JPN6019003718, 28 February 2015 (2015-02-28), pages 5973 - 5981, ISSN: 0004384697 * |
PROCEEDINGS OF SPIE, vol. 9166, JPN6019003725, 27 August 2014 (2014-08-27), pages 1 - 916612, ISSN: 0004384694 * |
PROGRESS IN BIOMEDICAL OPTICS AND IMAGING, vol. 9338, JPN6019003728, 9 February 2015 (2015-02-09), pages 933813 - 1, ISSN: 0004384695 * |
RCS ADV., vol. 6, JPN6019003713, 2016, pages 55568 - 55576, ISSN: 0004384691 * |
THE INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, vol. 38, JPN6019003716, 2006, pages 1530 - 1539, ISSN: 0004384692 * |
Also Published As
Publication number | Publication date |
---|---|
US20170049891A1 (en) | 2017-02-23 |
KR20200096329A (ko) | 2020-08-11 |
KR102145331B1 (ko) | 2020-08-18 |
TW201711705A (zh) | 2017-04-01 |
JP6826105B2 (ja) | 2021-02-03 |
WO2017029501A1 (en) | 2017-02-23 |
EP3337510A1 (en) | 2018-06-27 |
CN108289956A (zh) | 2018-07-17 |
TWI653050B (zh) | 2019-03-11 |
KR20180040616A (ko) | 2018-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wagner et al. | Quantum dots in biomedical applications | |
Ali et al. | Red fluorescent carbon nanoparticle-based cell imaging probe | |
Biju et al. | Bioconjugated quantum dots for cancer research: present status, prospects and remaining issues | |
Selvan et al. | Functional and multifunctional nanoparticles for bioimaging and biosensing | |
Jin et al. | Application of quantum dots in biological imaging | |
JP5662431B2 (ja) | 癌の光線力学療法のための標的化されたナノフォトメディスン | |
Morselli et al. | Luminescent copper indium sulfide (CIS) quantum dots for bioimaging applications | |
Gulia et al. | ZnO quantum dots for biomedical applications | |
JP6923956B2 (ja) | エクソソーム−コンジュゲートされた量子ドットナノ粒子、並びにそれを用いたエクソソーム及び癌の検出方法 | |
JP6826105B2 (ja) | 5−アミノレブリン酸がコンジュゲートされた量子ドットナノ粒子 | |
Hashemkhani et al. | One-step aqueous synthesis of anionic and cationic AgInS2 quantum dots and their utility in improving the efficacy of ALA-based photodynamic therapy | |
TW201812301A (zh) | 使用量子點靶向及操作粒線體功能的探針 | |
Dhas et al. | Organic quantum dots: An ultrasmall nanoplatform for cancer theranostics | |
JP2020519565A (ja) | 光応答性量子ドット薬物送達システム | |
US20200306377A1 (en) | Methods for enhancing 5-aminolevulinic acid-based medical imaging and phototherapy | |
US20180092815A1 (en) | Polymerizable quantum dot nanoparticles and their use as therapeutic, ablation and tattooing agents | |
WO2020120970A1 (en) | Methods for enhancing indocyanine green medical imaging and phototherapy | |
Priya et al. | Quantum Dot-based Bio-conjugates as an Emerging Bioimaging Tool for Cancer Theranostic-A Review | |
Maleki et al. | Functionalized quantum dot–based nanomaterials for cancer therapy | |
Santra et al. | Quantum dots for cancer imaging | |
Qu et al. | DOX-CONJUGATED HIGH-QUALITY AgZnInS QDs FOR REVERSAL OF MULTIDRUG RESISTANCE | |
Mansur et al. | Fluorescent Nanohybrids: Cancer Diagnosis and Therapy | |
Ceroni | Luminescent copper indium sulfide (CIS) quantum dots for bioimaging applications | |
BR102015012624A2 (pt) | Immunoconjugados fluorescentes based on the association of quantum points, quitosane and antibodies, process of obtaining and using |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180416 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180416 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190212 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190711 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191217 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200313 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200514 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200616 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201112 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210104 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210114 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6826105 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |